• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study to explore Fuchs' dystrophy genetics


Cleveland-Twenty-three sites will collect data for anationwide study on the genetics of Fuchs' endothelial cornealdystrophy (FECD), which afflicts about 1% of the generalpopulation.

Cleveland-Twenty-three sites will collect data for a nationwide study on the genetics of Fuchs' endothelial corneal dystrophy (FECD), which afflicts about 1% of the general population.

Researchers explore the genetic causes of the disease by collecting data from FECD patients and their family members.

Identification of the genes that may contribute to the development of FECD would be useful for family counseling; studying disease progression; implementation of corneal transplant surgery, if severe; and ultimately, gene modulation and therapy to delay or prevent its progression.

Investigators from the Vision Research Coordinating Center and the department of epidemiology and biostatistics at University Hospitals of Cleveland and Case Western Reserve University School of Medicine will conduct the study, which is funded by a 5-year grant from the National Eye Institute of the National Institutes of Health. The FECD Genetics Multicenter Study will be headquartered at University Hospitals and Case.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.